Retatrutide is an investigational triple-agonist peptide that activates three hormone receptors at once: GLP-1, GIP and glucagon. The “GLP-3” label is informal shorthand, not an official class name. It circulates in research circles because retatrutide builds on the GLP-1 and dual GLP-1/GIP compounds that came before it, adding a third pathway. Any GLP 3 peptide you encounter is, in practice, a reference to this molecule.
Why does it matter? Because each receptor shapes appetite, glucose handling and energy expenditure in a different way, and acting on all three is…
